title: Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
abstract: Cytarabine ocfosfate (SPAC) was administered orally to 19 patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SPAC was administered at doses of 200-300 mg/day for more than 14 days with granulocyte colony-stimulating factor (G-CSF). Four of the 12 patients with AML and 1 of the 7 patients with MDS achieved complete remission (CR) after one cycle of SPAC treatment. Especially, 3 of the 6 patients with newly diagnosed AML achieved CR. Major side effects of SPAC were myelosuppression and tolerable gastrointestinal disorders. The treatment with SPAC is a therapeutic option in elderly patients or patients with organ failure.
authors.affiliation: Department of Internal Medicine, Toyama Prefectural Central Hospital, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Okumura
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Takamatsu
authors.forename: T
authors.initials: T
authors.lastname: Katoh
authors.forename: M
authors.initials: M
authors.lastname: Murashima
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Yamauchi
authors.forename: S
authors.initials: S
authors.lastname: Matano
authors.forename: T
authors.initials: T
authors.lastname: Chuhjo
authors.forename: M
authors.initials: M
authors.lastname: Takeshima
authors.forename: H
authors.initials: H
authors.lastname: Kaya
authors.forename: S
authors.initials: S
authors.lastname: Ohtake
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Matsuda
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001088:Arabinonucleotides / Q000008:administration & dosage*; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D016179:Granulocyte Colony-Stimulating Factor; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D003568:Cytidine Monophosphate